Results 1 to 10 of about 14,908,548 (354)

A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training [PDF]

mAbs
Antibodies must bind their targets with high affinity and specificity to achieve useful therapeutic activity. They must also possess suitable developability properties (e.g.
Ammar Arsiwala, Rebecca Bhatt, Lood van Niekerk, Porfirio Quintero-Cadena, Xiang Ao, Adam Rosenbaum, Aanal Bhatt, Alexander Smith, Yaoyu Yang, KC Anderson, Lucia Grippo, Xing Cao, Rich Cohen, Jay Patel, Joshua Moller, Olga Allen, Ali Faraj, Anisha Nandy, Jason Hocking, Ayla Ergun, Berk Tural, Sara Salvador, Joe Jacobowitz, Kristin Schaven, Mark Sherman, Sanjiv Shah, Peter M. Tessier, David W. Borhani   +27 more
doaj   +3 more sources

Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability [PDF]

Communications Biology, 2023
Designing effective monoclonal antibody (mAb) therapeutics faces a multi-parameter optimization challenge known as “developability”, which reflects an antibody’s ability to progress through development stages based on its physicochemical properties ...
Habib Bashour, Eva Smorodina, Matteo Pariset, Jahn Zhong, Rahmad Akbar, Maria Chernigovskaya, Khang Lê Quý, Igor Snapkow, Puneet Rawat, Konrad Krawczyk, Geir Kjetil Sandve, Jose Gutierrez-Marcos, Daniel Nakhaee-Zadeh Gutierrez, Jan Terje Andersen, Victor Greiff   +14 more
doaj   +3 more sources

PROPERMAB: an integrative framework for in silico prediction of antibody developability using machine learning [PDF]

mAbs
Selection of lead therapeutic molecules is often driven predominantly by pharmacological efficacy and safety. Candidate developability, such as biophysical properties that affect the formulation of the molecule into a product, is usually evaluated only ...
Bian Li, Shukun Luo, Wenhua Wang, Jiahui Xu, Dingjiang Liu, Mohammed Shameem, John Mattila, Matthew C. Franklin, Peter G. Hawkins, Gurinder S. Atwal   +9 more
doaj   +3 more sources

Computational design of therapeutic antibodies with improved developability: efficient traversal of binder landscapes and rescue of escape mutations [PDF]

mAbs
Developing therapeutic antibodies is a challenging endeavor, often requiring large-scale screening to produce initial binders, that still often require optimization for developability.
Frédéric A. Dreyer, Constantin Schneider, Aleksandr Kovaltsuk, Daniel Cutting, Matthew J. Byrne, Daniel A. Nissley, Henry Kenlay, Claire Marks, David Errington, Richard J. Gildea, David Damerell, Pedro Tizei, Wilawan Bunjobpol, John F. Darby, Ieva Drulyte, Daniel L. Hurdiss, Sachin Surade, Newton Wahome, Douglas E.V. Pires, Charlotte M. Deane   +19 more
doaj   +3 more sources

Assessing developability early in the discovery process for novel biologics

mAbs, 2023
Beyond potency, a good developability profile is a key attribute of a biological drug. Selecting and screening for such attributes early in the drug development process can save resources and avoid costly late-stage failures.
Monica L. Fernández-Quintero, Anne Ljungars, Franz Waibl, Victor Greiff, Jan Terje Andersen, Torleif T. Gjølberg, Timothy P. Jenkins, Bjørn Gunnar Voldborg, Lise Marie Grav, Sandeep Kumar, Guy Georges, Hubert Kettenberger, Klaus R. Liedl, Peter M. Tessier, John McCafferty, Andreas H. Laustsen   +15 more
doaj   +2 more sources

Blueprint for antibody biologics developability

mAbs, 2023
Large-molecule antibody biologics have revolutionized medicine owing to their superior target specificity, pharmacokinetic and pharmacodynamic properties, safety and toxicity profiles, and amenability to versatile engineering. In this review, we focus on
Carl Mieczkowski, Xuejin Zhang, Dana Lee, Khanh Nguyen, Wei Lv, Yanling Wang, Yue Zhang, Jackie Way, Jean-Michel Gries   +8 more
doaj   +2 more sources

Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics

mAbs, 2022
Therapeutic monoclonal antibodies and their derivatives are key components of clinical pipelines in the global biopharmaceutical industry. The availability of large datasets of antibody sequences, structures, and biophysical properties is increasingly ...
Rahul Khetan, Robin Curtis, Charlotte M. Deane, Johannes Thorling Hadsund, Uddipan Kar, Konrad Krawczyk, Daisuke Kuroda, Sarah A. Robinson, Pietro Sormanni, Kouhei Tsumoto, Jim Warwicker, Andrew C.R. Martin   +11 more
doaj   +2 more sources

Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling

mAbs, 2023
In silico assessment of antibody developability during early lead candidate selection and optimization is of paramount importance, offering a rapid and material-free screening approach.
Eliott Park, Saeed Izadi
doaj   +2 more sources

Developability considerations for bispecific and multispecific antibodies

mAbs
Bispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessment of
Alaa Amash, Gesa Volkers, Patrick Farber, Daniel Griffin, K. Shawn Davison, Allison Goodman, Raffi Tonikian, Aaron Yamniuk, Bryan Barnhart, Tim Jacobs   +9 more
doaj   +2 more sources

High concentration formulation developability approaches and considerations

mAbs, 2023
The growing need for biologics to be administered subcutaneously and ocularly, coupled with certain indications requiring high doses, has resulted in an increase in drug substance (DS) and drug product (DP) protein concentrations.
Jonathan Zarzar, Tarik Khan, Maniraj Bhagawati, Benjamin Weiche, Jasmin Sydow-Andersen, Alavattam Sreedhara   +5 more
doaj   +2 more sources